rss
Ann Rheum Dis 2005;64:1294-1298 doi:10.1136/ard.2004.030924
  • Extended report

Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial

  1. J Fransen1,
  2. H Bernelot Moens2,
  3. I Speyer3,
  4. P L C M van Riel1
  1. 1Department of Rheumatology, University Medical Centre Nijmegen, Nijmegen, Netherlands
  2. 2Department of Rheumatology, Medical Spectre Twente, Enschede, Netherlands
  3. 3Department of Rheumatology, Bronovo Hospital, The Hague, Netherlands
  1. Correspondence to:
    J Fransen
    Department of Rheumatology, University Medical Centre Nijmegen, PO Box 9101, NL-6500 HB Nijmegen, Netherlands; j.fransenreuma.umcn.nl
  • Accepted 21 March 2005
  • Published Online First 13 April 2005

Abstract

Objective: To test the efficacy of standardised monitoring using the disease activity index DAS28 versus usual care on disease modifying antirheumatic drug (DMARD) prescription and disease activity in rheumatoid arthritis.

Methods: A 24 week cluster randomised trial. Rheumatology outpatient centres were randomised to systematic monitoring of disease activity using the DAS28 (12 centres, 205 patients) or usual care (12 centres, 179 patients). The aim for the DAS group was to reach a DAS28 score of ≤3.2 by changes in DMARD treatment, at the discretion of the rheumatologist and the patient.

Results: At baseline, disease activity was the same in both groups, with an overall mean (SD) DAS28 of 4.5 (1.2); 13% of the patients had a DAS28 of ≤3.2. At 24 weeks, 31% of patients in the DAS group had a DAS28 ≤3.2, while in the usual care centres this was 16% (p = 0.028). DMARDs were changed on average in 18% of visits in the DAS centres; in the 12 usual care centres they were changed on 8% of the visits (p = 0.013). The doses of methotrexate, sulfasalazine, and corticosteroids appeared to be higher in the DAS centres than in the usual care centres, but the differences were not significant.

Conclusions: In daily practice, systematic monitoring of disease activity in rheumatoid arthritis may lead to more changes in DMARD treatment, resulting in a larger number of patients with low disease activity.

Footnotes

  • Published Online First 13 April 2005

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. ard.2004.030924v1
    2. 64/9/1294 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.